Foghorn Therapeutics Inc. Form 8-K Summary
Business context and reporting period
Foghorn Therapeutics Inc. filed a Current Report on Form 8-K dated January 16, 2024, reporting a change in executive responsibilities. The filing does not provide quarterly or annual financial results.
Executive appointment
- Effective January 16, 2024, the board appointed Stephen J. DiPalma as Treasurer and interim Chief Financial Officer.
- The company is continuing its search for a permanent CFO.
- Mr. DiPalma is a managing director at Danforth Advisors, LLC, which already provides strategic and financial consulting services to Foghorn.
- Under an agreement between Foghorn and Danforth, Mr. DiPalma will provide interim CFO services. Foghorn will pay Danforth an agreed hourly rate and reimburse expenses.
- Mr. DiPalma, age 65, has served as a Danforth managing director since April 2014 and has prior CFO experience with public and private companies.
- The filing states that he has no family relationships with Foghorn’s executive officers or directors and that no other appointment arrangements or understandings exist.
Financial metrics and liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating or financial metrics.
Material changes, outlook, and risks
The material change is the immediate appointment of an interim CFO while the permanent CFO search continues. The use of an external consultant creates hourly service fees and expense reimbursements, but the filing does not disclose the applicable rate, expected cost, duration, or other material terms. No additional risks, contingencies, or unusual financial items are identified.
Key facts for investors to verify
- Duration and status of the permanent CFO search.
- Hourly rate, expected expenses, and total potential cost of Danforth’s interim CFO services.
- Whether the interim appointment affects financial reporting controls, filing timelines, or other corporate functions.
- Subsequent disclosures regarding appointment of a permanent CFO or changes to the Danforth agreement.